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von Willebrand factor (vWF) is a multimeric glycoprotein essential for hemostasis after vascular injury, which
modulates platelet-surface and platelet–platelet interactions by linking platelet receptors to the extracellular
matrix and to each other. The crucial role of vWF in platelet function is particularly apparent when hemodynamic
conditions create blood flow with high shear stress. Through multiple functional domains, vWF mediates the
attachment of platelets to exposed tissues, where immobilized vWF is able to support a homotypic and/or
heterotypic self-association. The self-association of vWF is also supported by a rapidly expanding reservoir of
novel evidences that the thiol/disulfide exchange regulates vWF multimer size in the blood circulation. Moreover,
in addition to proteolysis and reduction of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin
type 1 motif, member 13), the regulation of vWF multimer size and self-association may depend on a disulfide
bond reductase activity ascribed to thrombospondin-1 (TSP-1). Along with the classical signaling pathways in
activated platelets, evidence is emerging that lipid rafts also play important roles in various phases of hemostasis
and thrombosis and facilitate the interaction between the key signaling molecules. Developments in these areas
will refine our understanding of the role played by vWF self-association in physiological hemostasis and
pathological thrombosis.
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vWF is a large multimeric plasma glycoprotein that plays
an important role in hemostasis and thrombosis. This
protein is encoded by a very large gene (180 kb, 52
exons) located at the tip of the short arm of chromo-
some 12, region 12p12-l2pter [1,2]. vWF is synthesized
by megakaryocytes and endothelial cells as pre-pro-vWF.
The pre-pro-vWF, composed of a 22-amino acid signal
peptide, a 741-amino acid propeptide and the 2050-
amino acid mature protein [3], undergoes extensive
post-translational processing, glycosylation and assembly
in the endoplasmic reticulum, Golgi and post-Golgi
[3-5]. vWF multimers synthesized in endothelial cells
or in megakaryocytes are stored in cytoplasmic gran-
ules, which are also called the Weibel-Palade bodies in* Correspondence: lsszq@mail.sysu.edu.cn
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reproduction in any medium, provided the orendothelial cells [6,7] or at the periphery of platelet
α-granules [8]. The mature monomeric protein is a
~250 kDa molecule containing 12 N-linked and 10
O-linked oligosaccharide chains [9]. Analysis of the
amino acid sequence shows that each vWF monomer
contains modular domains that are arranged in the order
D’-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK. Each vWF
monomer has binding sites for fibrin, platelet glycopro-
tein Ib, IIb/IIIa (GPIb, GPIIb/IIIa) and clotting factor
VIII (FVIII) [3]. In the flow of circulation, large bundles
or filaments of disulfide-linked vWF multimers of 500 to
20,000 kDa have been found [10]. It is believed that
under normal conditions the size of vWF multimers is
precisely controlled by ADAMTS13-mediated proteolysis
of the Tyr1605-Met1606 peptide bond in the A2 domain
[11,12]. Genetic or acquired deficiency of ADAMTS13
causes thrombotic thrombocytopenic purpura (TTP), a
life-threatening disease, in which microvascular thrombi
forms in arterioles and capillaries [10], while a paucity
of large vWF multimers caused by mutations in the A2
domain is associated with the bleeding disorder, type 2Ad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Potential intradomain interaction of vWF. Partial
structure of pro-vWF is shown from vWFpp to vWF A3 domain.
①vWFpp binding to the D’D3 domain of mature vWF occurs in
the circulation and attenuates platelet adhesion and activation.
②The D’D3 domain of von Willebrand factor shields the A1 domain
in its resting conformation and negatively regulates the binding of
A1 domain to GPIb. ③N-terminal flanking region of A1 domain
(amino acids Gln1238-Glu1260) in von Willebrand factor stabilizes
the structure of A1A2A3 complex and modulates platelet activation
under shear stress. ④The recombinant A2 domain of von Willebrand
factor specifically binds to the active conformation of A1 domain
and blocks the interaction with GPIb.
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there were a number of studies that focused on the role
of ADAMTS13 in regulating vWF size under hydro-
dynamic shear [15]. Recently, increasing amount of
evidences suggest the self-association of vWF may be an
additional mechanism regulating the protein size in
circulation, implying a critical impact of vWF self-
association on hemostasis and thrombosis [16-18]. How-
ever, little is known about the mechanism by which
plasma vWF self-associates under high shear stress at
site of vascular rupture. This article reviewed recent
literature on vWF self-association and we provide a sum-
mary model to explain dynamic regulation of vWF self-
association (by multidomain interaction, hydrodynamic
shear force or thiol/disulfide exchange) and its effect on
the complex signal pathways of platelet activation.
Functional domain of vWF and the interaction
with platelet
The vWF subunit comprises several domains of which
specific functions have been identified [3]. The D’-D3
domains are potential binding sites for P-selectin [19,20]
and are involved in vWF multimerization [21]. Much of
the functional activity of vWF multimers resides within
the three tandem A domains, A1, A2, and A3. The bind-
ing of the A1 domain to GPIb, which initiates rolling
interactions, is the first step in the formation of a
hemostatic plug at the site of vascular injury [22]. More-
over, the A1 domain has binding sites for heparin, the
bacterial glycopeptide antibiotic ristocetin, the snake
venom botrocetin and collagen [3,23-28]. The A2
domain situated between A1 and A3 domain lacks long-
range disulphide bonds. The cleavage of force-sensing
A2 domain by ADAMTS13 depends on hydrodynamic
shear force-dependent unfolding of the A2 domain,
and occurs at the Tyr1605–Met1606 bond within the A2
domain [11]. The size of the vWF multimers is modu-
lated by the ADAMTS13 domain, depending on the
rheological forces and calcium ion [29]. The A3 domain
is the binding site for fibrillar collagen type I and III
[25,26,30]. The structural change of A3 domain enables
the binding of the A1 domain to GPIb consisting of a
disulfide-linked α chain and β chain [31,32]. The initial
step mediated by A1 domain is followed with platelet
activation and stable adhesion via the irreversible inter-
action between C domain and GPIIb/IIIa by RGDS
within the C domain, which initiates and expands the
platelet aggregation cascade [22,33,34]. The vWF C1 and
C2 domains are involved in platelet adhesion to poly-
merized fibrin at high shear stress [35]. The CK domain
is a prerequisite to vWF tail-to-tail dimerization [36].
Thus, the functional domains within vWF are potential
elements that mediate intradomain or interdomain inter-
action contributing to vWF self -association.Multiple domains interaction contributing to vWF
self-association
vWF self-association was first reported by Savage et al.
[37] who showed that fluid-phase vWF multimers could
homotypically associate with vWF multimers that were
immobilized onto a collagen surface or glass. These self-
associated vWF multimers supported platelet adhesion
under shear stress and vWF multidomain interaction
potentially contributes to vWF self-association under
shear force. Numerous studies have been carried out in
order to identify the exact domains that contribute to
the homotypical self-association. It has been shown that
vWF self-association may involve the vWF propeptide
(vWFpp), D’D3, N-terminal flanking region of A1
domain, A1 and A2 domain (Figure 1). However, the
potential function of the A3 domain in homotypical
association is questioned, as blocking or devoiding A3
domain in both soluble and immobilized wild type vWF
(WT-vWF) contributed to the same platelet adhesion as
that observed when soluble and immobilized WT-vWF
were used in a flow studies [37]. A close relationship be-
tween the A1 and A2 domains in vWF has also been
demonstrated. For instance, one study suggested that the
A1 domain inhibited the cleavage of the A2 domain, and
that the interaction of platelet GPIbα or heparin with
the A1 domain terminated such inhibition, thus making
the A1A2A3 domain more susceptible to cleavage by
ADAMTS13 [38]. Another study has advanced our
understanding of intradomain interaction by showing
that the recombinant A2 domain polypeptide can specif-
ically recognize the GPIbα-binding conformation in
the A1 domain activated by the modulator ristocetin or
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tions impeded the accessibility of the A1 domain. Inter-
estingly, in contrast to plasma vWF, the A2 domain
bound to the ultra-large vWF (ULvWF) multimers or a
recombinant vWF-A1A2A3 polypeptide containing a
gain-of-function mutation (R1308 L) of type 2B vWD in
the absence of ristocetin [39].
It has been recently shown that the only binding site
for vWFpp in mature vWF is in its D’D3 domain and
vWFpp has the ability of partially reducing platelet adhe-
sion and activation by reduce the binding affinity of the
VWF-A1 domain for platelet GpIbα [40,41]. The results
presented in this study demonstrated that deletion of the
D’D3 region in vWF facilitated the binding of vWF to
GPIbα, suggesting an inhibitory role for this region. The
isolated D’D3 region inhibited the GPIbα interaction
with a vWF deletion mutant lacking this region, indicat-
ing that intradomain interactions limit the accessibility
of the A1 domain. Interestingly, N-terminal region of
the A1 domain (amino acids Gln1238-Glu1260) was also
reported to modulates the interaction between vWF and
GPIbα [42]. The N-terminal region of vWF between the
D4 and cystine-knot domains was visualized for the first
time to form a rod at the acidic pH of the trans-Golgi
and Weibel-Palade bodies. In addition, the A2, A3 and
D4 domains were observed to assembly a raceme with
three pairs of opposed, large, flower-like domains by
electron microscopy [43]. These observations shed light
on the interdomain interaction attributing to vWF self-
association that occurs during the biogenesis of vWF
prior to its secretion into the vasculature. In addition to
mimicking the in vivo environments for vWF assembly,
there were reports that the proteolytic vWF-fragments
SpII (1366–2050) and SpIII (1–1365) respectively inhib-
ited the interaction between vWF and biotinylated vWF
(b-vWF) by 70% and 80%, as measured by ELISA
analysis, suggesting that SpII and SpIII contributed to
vWF self-association [44]. An interesting hypothesis was
proposed that the same multiple-domain interaction
accounted for the stabilization of the globular structure
of vWF under rest state. Once activated by immobilizing
or shear force, homotypic and/or heterotypic region self-
association might occur [44]. Despite extensive studies,
however, the mechanism by which intradomain inter-
action mediates vWF self-association with each other
has not been clearly elucidated. Further studies are thus
required in order to identify the precise nature of the
intradomain or interdomain interaction attributing to
vWF self-association.
Shear force and functional self-association of vWF
Hemostasis and thrombosis have significance beyond the
scope of blood diseases, and they have been extensively
studied in the context of the dynamic nature of theprotein and hemorheology. The shear force in blood
circulation is the crucial determinant of vWF self-
association in different systems. vWF undergos a self-
association process when the conformational state of
vWF is changed by chemical potential of allosteric
effector such as ristocetin, even in the absence of hydro-
dynamic shear stress and protein adsorbing surface
[44,45]. The mechanism of ristocetin induced self-
association might be related to the ability of ristocetin to
specifically bind to the A1 domain of vWF and trigger a
large conformational change of the vWF molecule,
which is responsible for its binding to platelet GpIbα
[46]. On the other hand, individual molecules can self-
associate not only under shear force [37,47,48], but also
in a static condition [49]. It was shown previously that
soluble VWF multimers isolated from human plasma
self-assemble to a network of fibers immobilized on a
collagen matrix as observed under immunofluorescence
microscopy and were functionally active to bind platelets
under the condition of the shear flow [47]. Atomic
force microscopy images were then used to elucidate
the nanostructure of VWF fibers and illustrate self-
association and -aggregation of several filamentous mul-
timers [47]. Similarly, the nature of the assembly that is
formed by VWF self-association in solution induced by
ristocetin binding was clarified by atomic force micros-
copy [45]. vWF was shown to adhere to the collagen
coated surface at high shear rates also form a spider web
like network, which represents a very adhesive substrate
for blood platelets [50]. This team monitored the ad-
sorption process of multiple vWF fibers on an adsorbing
collagen substrate in the planar micro-fluid device. They
were able to follow the formation of an immobilized
network that constitutes a “sticky” grid necessary for
blood platelet adhesion under high shear flow. At the
same time, Shankaran et al. have made a significant con-
tribution to our understanding of the process of vWF
self-association in suspension induced by the hydro-
dynamic forces. This study applied western blotting and
densitometry analysis to confirm the occurrence of lar-
ger vWF moieties in sheared samples, suggesting that
vWF self-associated under hydrodynamic shear [51].
Also, flow studies revealed that soluble vWF over a
vWF-coated surface underwent dynamic and reversible
“homotypic” self-association that facilitated platelet ad-
hesion, whereas immobilized BSA, human fibrinogen,
and fibronectin could not substitute for vWF in this
process [52]. Recent experimental polymer physics stud-
ies had paid significant attention to the mechanism by
which vWF unfolded to self-associate at the sites of vas-
cular injury [53-55]. vWF stretching was further elabo-
rated from a polymer physics perspective to demonstrate
that elongation flows, which appear during vasoconstric-
tion or stenosis, were the most principal factors in the
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ent triggers in blood clotting [56]. In vivo, shear force
could promote conformational changes in vWF and
enable vWF to interact with subendothelial proteins and
platelets, thus promoting primary hemostasis. Shear
force might act as a key factor in the dynamic regulation
of vWF self-association. This, together with the in vitro
and in vivo data, makes a compelling case for shear force
having a biologically relevant role in the control of vWF
self-association (Figure 2)
Base on the above findings and considerations, some
studies validated that purified plasma vWF multimers
significantly increased the numbers of strings on
histamine-stimulated human umbilical vein endothelial
cells (HUVECs) under flow conditions [57]. It is note-
worthy that the sheared plasma vWF molecules resem-
ble polydispersed coils in contrast to the rodlike
morphology of unsheared samples [51]. Recently, vWF
was observed to transit from a loosely coiled ball to a
stretched structure in response to shear force. The
unfolding process was reversible since once the hydro-
dynamic shear force was reduced to 5,000s-1, vWF
immediately relaxed back to its compact state [58,59].
There is other evidence suggesting that relaxation
process of stretched vWF bundles formed by hydro-
dynamic stress proceeded through hopping events be-
tween a multitude of minima. The longest relaxation
time was found to be dominated by the internal confor-
mations and effective friction within the bundle, consist-
ent with current ideas of vWF self-association [60].
Up to now, little is known about the dynamic andFigure 2 Model for regulation of plasma vWF multimers self-associati
are folded into tangled and condensed coils. In this folded conformation, t
bindings of vWF to platelet receptors. Under the high shear stress, globula
each other. The lateral associations can seek to maximize their exposure in
GPIb in multiple vWF A1 domains.mechanical characteristics of such vWF fibers. Physio-
logical and pathological levels of shear stresses (50
and 100 dynes/cm-2) were demonstrated to modify the
vWF adhesion activity by promoting the formation of di-
sulfide bonds which may increase vWF multimer size
[61]. It was proposed that high shear stress elongates
globular plasma vWF multimers, promotes covalently
association of vWF by forming interchain disulfide
bonds, and increases binding avidity and bond strength
for platelet GPIb.
Thiol/disulfide exchange and vWF self-association
The regulation of vWF multimer size involves a series of
coordinated and linked transitions, especially conform-
ational changes of vWF regulated by blood flow and
thiol/disulfide exchange. On the one hand, vWF multi-
mers, which conformationally change from a loosely
coiled ball to an elongated structure in response to tur-
bulent flow, are the preferred substrate for TSP-1 and
ADAMTS13. TSP-1 may reduce vWF multimers size by
reducing the disulfide bonds. On the other hand, vWF
multimers secreted by HUVECs can self-associate in di-
verse patterns, forming twisted bundles and networks on
endothelial cells when exposed to laminar flow. The
shear-mediated vWF reassembling into larger structures
may represent an efficient way to allow locally the pres-
ence of molecular species needed for thrombus forma-
tion (Figure 3). Evidence is available that the thiol/
disulfide state of vWF multimers may serve as a critical
regulator of vWF activity, which is supported by many
experimental observations [45,62,63]. In the case ofon under shear stress. Plasma vWF multimers circulated in blood
he intradomain interaction may block the A domain and prevent the
r plasma vWF multimers are stretched to covalently associate with
order to augment binding capacity and bond strength for platelet
Figure 3 Model for regulation of the balance of vWF self-association and two forms of flows in blood vessel. A: The regulation of vWF
multimer size equilibrates between reducing vWF multimer size and increasing vWF multimer size. Reducing vWF multimer size: In turbulent
flow, the elongated vWF multimers are reduced by TSP-1 and ADAMTS13 due to the elevated activities of TSP-1 and ADAMTS13 (cleavage and
reduction activity) in response to turbulent flow and can’t self-associate. Increasing vWF multimer size: In laminar flow, the elongated vWF
multimers that tend to flow in parallel are undesirable substrates of TSP-1 and ADAMTS13, because some corresponding sites of vWF are buried
in vWF fibers. It is speculated that the paralleled vWF multimers are more prone to self-associate to form vWF fibers. B: The turbulence and
laminar flow are two of the complex and diverse forms of flow in blood. Turbulent flow is always highly irregular, in which the blood proteins
tend to move in different directions at different speeds. vWF multimers undergo conformational change from a loosely coiled ball to an
elongated structure in turbulent flow. Laminar flow in a cylindrical vessel can be visualized as a series of fluid layers with different velocity.
The laminae close to the vessel wall have less velocity than those near the center (depicted schematically by arrows of different length).
The elongated vWF multimers tend to be oriented to each other in laminar flow.
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endothelial surface, vWF self-association was mediated
by covalent interaction, as the formation and propaga-
tion of ULvWF strings were dose-dependently reduced
by blocking thiols on vWF with N-ethylmaleimide
(NEM) [64]. Further studies unveiled that the mechan-
ism underlying formation of the vWF strings involves
in cysteine thiol/disulfide exchange as the formation of
the strings was inhibited by thiol alkylation [61] and
the string structure was disrupted by the small thiol, N-
acetylcysteine (NAC) [62]. Xie et al. hypothesized that
redox regulation was possibly involved in further con-
trolling of vWF multimer size [65]. This group claimed
that a protein disulfide bond reductase in conditional
medium from in vitro cultures of various endothelial cell
lines could reduce plasma vWF multimer size associated
with formation of new thiols and that its action could be
ablated by the thiolblocking agents, iodoacetamide,
NEM or E-64. As mentioned above, this active compo-
nent has been isolated from human endothelial cellconditional medium and shown to be the trimeric glyco-
protein, TSP-1. TSP-1 reduces the average multimer size
of vWF secreted by endothelial cells through forming
thiol-dependent complexes of TSP-1 and vWF. More-
over, vWF-reducing activity of TSP-1 is in the calcium-
binding/C-terminal sequence and required a free thiol at
position 974 [66]. It was confirmed that the higher the
plasma TSP-1/vWF molar ratio, the smaller the average
vWF multimer size [67]. Surprisingly, two TSP-1 knock-
out mice studies showed that TSP-1 might actually keep
unfolded endothelium-bound and subendothelial VWF
from degradation by plasma ADAMTS13, possibly by
competing for A3 domain within vWF [68,69]. However,
it is important to note that both TSP-1 and vWF stored
in platelet α-granules are released upon platelet activa-
tion [8,70]. TSP-1 influences plasma and platelet vWF
multimeric size differently and may be more relevant for
the control of the vWF release from platelets (Figure 3).
Meanwhile, there were the parallel and cooperative
evidences that the disulfide-bond-reducing activity of
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and increase platelet adherence of plasma-type vWF
multimers induced by high fluid shear stress [47].
ADAMTS13 contains TSP1 repeats and cysteine-rich
domain [71-73]. The cysteine-rich, TSP1 repeats and
CUB domain located at C-terminal region of ADAMTS13
primarily target disulfide bonds in the C-domain of
plasma vWF multimers induced by high shear stress, thus
impeding covalent lateral association and decreasing
platelet recruitment on plasma vWF multimers [74].
Recent insights in the vWF self-association led to the
identification of cysteine thiols targeted by ADAMTS13
that resides in the vWF C-domain [18]. Alkylation assay
by MPB revealed that free thiols buried in the native
protein were detected in vWF in the presence of SDS and
in the condition of heat [75].
Intriguingly, mature vWF, both purified from plasma
and made recombinantly, contains unpaired cysteine
thiols [61,74,75] that are localized in the N terminal of
D3 domain and C-terminal of C domains [57,61,74]. The
entire array of cysteines in vWF is listed in Table 1. Nine
free Cysteine thiols in plasma vWF are in the D3 and
C domains, with seven of the nine centering on the
C domain [61]. In contrast to plasma vWF, ULvWF did
not contain surface exposed thiols [61]. And the adhe-
sion of plasma vWF to ULvWF secreted from histamine
stimulated HUVECs could be ablated by the thiol block-
ing agents NEM and MPB, which could also directly
block the formation of ULvWF strings [57]. The shear
focre on vWF generated by a cone and plate viscometer
could promote the formation of disulfide bonds by
decreasing thiol exposure. And likewise, the shear-
induced binding of vWF to platelets was blocked by
MPB, which predominantly binds to the exposed thiols
[61]. Recently, a thiol/disulfide mechanism of vWF self-
association was elucidated through unpaired cysteines in
the C-terminal part of vWF including Cys2431-Cys2453
and nearby Cys2451-Cys2468 by mutagenesis studiesTable 1 Potential cysteines involved in vWF self-association
Domain region Identified disulfide b
D’ domain 767↔ 808 776↔




A domain 1272↔ 1458 (A1) 1669↔ 1
A3-D4 domain 1879↔ 1904 1899↔
D4 domain 1950↔ 2085 1972↔
C domain 2724↔ 2774 2739↔
2448, 2451 2490, 2
“↔” represents disulfide bond, free cysteines are shown in bold. The sequence loca[18,61]. In short, Cys2431 thiolate reduced from
Cys2431-Cys2453 disulfide bond by a reductase in one
molecule of vWF attacks the same disulfide bond in
another vWF molecule to form the dimmer. Then the
Cys2451 thiolate of one of the molecules in the dimer
attacks the Cys2431-Cys2453 disulfide bond of the third
molecule, adding third vWF molecule to the dimer.
Other molecules can then add by the same reaction,
thus leading to the formation of vWF multimers [18].
Although Cys2431-Cys2453 in the C2 domain contri-
butes to self-association of vWF, the mature monomeric
vWF subunit contains 169 cysteines that are involved in
either intra-subunit or inter-subunit vWF disulfide bond
formation [36], as shown in Table 1, and there might be
other cysteines in vWF involved in self-association.
The synergistic mechanism of the main platelet receptors
involved in vWF self-association
vWF binding to GPIb-IX-V is known to induce activa-
tion of GpIIb/IIIa which finally results in GpIIb/IIIa-
dependent platelet aggregation [76]. The GPIb-IX-V
mediated platelet activation depend on the activation of
phospholipase Cγ2 (PLCγ2) after vWF binding [77,78].
Succeedingly, activated PLCγ2 promotes the production
of inositol 1, 4, 5 trisphosphate (IP3) and diacylglycerol
(DAG) by hydrolyzing phosphatidylinositol 4,5 bispho-
sphate [79]. IP3, a small and fast diffusing water soluble
molecule, binds to the IP3 receptor (IP3R) on the platelet
dense tubular system (DTS). The IP3R, designated as
calciumselective cation channel, allows efflux of Ca2+
from the DTS, thus increasing the cytoplasmic Ca2+
level [80]. Increased Ca2+ level activates “Ca2+ and dia-
cylglycerol regulated guanine nucleotide exchange factor
I” (CalDAG-GEFI) [81,82], which in turn promotes the
activation of Rap1b, a small GTP binding protein. Rap1b
is critical for GpIIb/IIIa activation and platelet function
[83] by regulating cytoskeletal rearrangements through
interactions with Rap1-interacting adaptor moleculeond/cysteines in vWF multimers
804 810↔ 821
1031 898↔ 993 914↔ 921
1111 1089↔ 1091 1126↔ 1130
1165 1196↔ 1199 1234↔ 1237
670 (A2) 1686↔ 1872 (A3)
1940 1927↔ 2088
2123 1993↔ 2001
2788 2750↔ 2804 2754↔ 2806
491 2453, 2528 2533
tions include the signal peptide and propeptide sequences.
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“activation complex” containing Rap 1, RIAM and talin
that redistributes to the plasma membrane and activates
GpIIb/IIIa [85-87]. Recent evidence has shown that
kindlin3 is also involved in GpIIb/IIIa activation, as mice
with dysfunctional kindlin3 have defective GpIIb/IIIa
activation despite normal talin expression, resulting in
severe bleeding and resistance to arterial thrombosis
[88]. Therefore, the PLCγ2-dependent mobilisation of
calcium from intracellular stores plays a critical role in
the activation of GpIIb/IIIa upon vWF binding to GPIb-
IX-V (Figure 4) [89].
In normal circulation within intact vasculature, most
platelets never have the access to interact with the endo-
thelial surface during their whole lifetime. However, at
sites of vascular injury, platelets promptly adhere to the
subendothelial extracellular matrix bridged by vWF to
limit hemorrhage and promote tissue healing [80]. The
results were verified by the observation that transient
interactions of platelet-receptor GpIb with immobilized
vWF mediate the rolling of platelets at sites of vascular
damage, during which rolling reduces platelet velocity
and prolongs the contact time with reactive components
of the cell matrix [90]. Particularly, platelets could read-
ily bind to extremely long “beads-on-a-string” structuresFigure 4 Proposed mechanism of associated vWF activating GPIIb/IIIα
disulfide bond. Associated vWF binds to GPIb-IX-V through A1 domain (in
to high affinity. After the conformation alteration, activated GPIIb/IIIa binds
The generally known signaling pathway from GPIb-IX-V to GPIIb/IIIa is show
signaling. Here we have depicted the events subsequent to the interaction
increases the level of intracellular calcium, which is regulated by PLCγ2 der
diacylglycerol (DAG). The elevated Ca2+ and DAG together increase CalDA
of an “activation complex” consisting of RapI, RIAM and talin, which finally
pathway from GPIb-IX-V to GPIIb/IIIa is shown in the right platelet. On the
GPIb-IX-V and GPIIb/IIIa in their respective local membrane when vWF self-
signaling in contrast with the activation of receptor itself by ligand only. Th
their adaptor proteins in close proximity manner.of newly released ULvWF formed under laminar flow
that were visible by phase-contrast microscopy [13].
It was in line with the study showing that platelets spon-
taneously bound to a subset of vWF strings secreted
from histamine stimulated HUVEC in a GPIb dependent
manner [62,91]. Importantly, platelets adhered to ULvWF
fibers expressed P-selectin and bound PAC-1 (antibody
against GpIIb/IIIa), suggesting that the adhesion of plate-
lets to ULvWF fibers induced rapid platelets activation
[48]. Recent elegant studies showed that fluid shear in
circulation could increase the effective size of vWF bind-
ing to platelet GpIbα via protein self-association, which
triggers mechanotransduction and platelet activation by
enhancing the drag force applied on the cell-surface
receptor, implying that vWF self-association is necessary
for platelet activation (Figure 4) [63].
Additionally, lipid rafts may serve as a platform to
concentrate activated GpIb-IX-V and GpIIb/IIIa in their
respective local membrane when vWF self-association
occurs and attaches. The GPIb-IX-V complex was first
reported to localize to membrane microdomains by
Dorahy et al. in 1996 [59], but these researchers did not
investigate the functional consequences of this associ-
ation. Increasing evidence is emerging that GPIb-IX-V
and GpIIb/IIIa were reported to localize to lipid rafts by. Lateral associated vWF are formed by different multi-vWF through
yellow), leading to a shift of GPIIb/IIIa conformation from a low-affinity
to the C domain (in red) of associated vWF by RGDS within C domain.
n in the left platelet which depends on the out-inside and inside-out
between vWF and GPIb-IX-V. The activated GPIb-IX-V subsequently
ived second messengers inositol 1,4,5 trisphosphate (IP3) and
G-GEFI activity that in turn activates RapIb. This leads to the formation
cooperates with kindlin3 to activate GPIIb/IIIa. Another possible
other hand, lipid rafts may serve as a platform to concentrate activated
association occurs. The formation of lipid rafts is required for out-inside
ey can change the recruitment of these intracelluar receptors and
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Although relative quantities of GpIIb/IIIa in raft and
non-raft fractions did not change on activated platelet,
vWF would increase the percentage of GpIb-IX-V
located to lipid raft [93]. Disruption of rafts by choles-
terol depletion markedly inhibited virtually every aspect
of GPIb-IX-V complex function, which results in the
inside-out activation of the integrin GpIIb/IIIa, and sub-
sequent platelet aggregation [93]. We speculated that
lipid rafts might play a key role in signaling after engage-
ment of the complex by VWF self-association. Here, a
model is proposed to explain effects of lipid rafts forma-
tion of on platelet activation upon stimulation by vWF
self-association (Figure 4). This model requires that
GPIb-IX-V complexes be clustered sufficiently close to
allow formation of this lipid rafts-ordered complex, and
may explain the requirement of rafts for subsequent
GPIIb/IIIa activation. This raft association of GPIb-IX-V
induced by self-associated vWF would induce GPIIb/IIIa
activation in a way different to the outside-in/inside-out
signal pathway in platelet activation discussed above.
Therefore, vWF self-association may be a cryptic factor
in the signaling pathway of platelet.
Conclusion
vWF self-association has been become increasingly
appreciated over the past several years. The self-
association ability of vWF represents an additional
mechanism that the circulating multimers interact in a
reversible manner with matrix-bound and endogenous
subendothelial vWF under conditions of hydrodynamic
shear. Conversely, the association is damped by increas-
ing cleavage by ADAMTS13 under fluid shear stress.
This reaction is likely to account for a majority of vWF
proteolysis after secretion and determines the distribu-
tion of circulating vWF multimers in vivo. The other
mechanism that has been shown to alter vWF self-
association is the reduction of the disulfide-bonds hold-
ing the subunits together, which led to the identification
of TSP-1 as a disulfide reductase involved in regulation
of vWF multimer size. We speculate that ADAMTS13/
TSP-1 and vWF self-association work together to regu-
late vWF multimer assembly and degradation, and func-
tional imbalances between the two sides are related
mechanistically to the problems of bleeding and throm-
bosis. It has been also indicated that a thiol/disulfide
mechanism of self-association of vWF involves in either
intra-subunit or inter-subunit vWF disulfide bond for-
mation, suggesting the possibility that the cysteines
exposed on plasma vWF or buried in might result in
self-association. Above all, vWF self-association binding
to GPIb-IX-V may trigger outside-in signals of platelet
activation through mechanotransduction applied on the
cell-surface receptor. In turn, ligand binding to GpIIb/IIIa is controlled by inside-out signals that modulate
receptor conformation and clustering. Further under-
standing of vWF’s dynamic self-association can provide
new approaches and theory evidences for a subject with
immediate physiological and signaling relevance.
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